AIM: The main purpose of this study was to estimate the SLC34A2 gene expression in normal ovary and different types of ovarian tumors. METHODS: We have investigated SLC34A2 gene expression level in papillary serous, endometrioid, unspecified adenocarcinomas, benign tumors, and normal ovarian tissues using real-time PCR analysis. Differences in gene expression were calculated as fold changes in gene expression in ovarian carcinomas and benign tumors compared to normal ovary. RESULTS: We have found that SLC34A2 gene was highly expressed in well-differentiated endometrioid and papillary serous ovarian carcinomas compared to low-differentiated endometrioid carcinomas, benign serous cystoadenomas and normal ovary. Analysis of SLC34A2 gene expression according to tumor differentiation level (poor- and well-differentiated) showed that SLC34A2 is up-regulated in well differentiated tumors. CONCLUSION: Upregulation of SLC34A2 gene expression in well-differentiated tumors may reflect cell differentiation processes during ovarian cancerogenesis and could serve as potential marker for ovarian cancer diagnosis and prognosis.
AIM: The main purpose of this study was to estimate the SLC34A2 gene expression in normal ovary and different types of ovarian tumors. METHODS: We have investigated SLC34A2 gene expression level in papillary serous, endometrioid, unspecifiedadenocarcinomas, benign tumors, and normal ovarian tissues using real-time PCR analysis. Differences in gene expression were calculated as fold changes in gene expression in ovarian carcinomas and benign tumors compared to normal ovary. RESULTS: We have found that SLC34A2 gene was highly expressed in well-differentiated endometrioid and papillary serous ovarian carcinomas compared to low-differentiated endometrioid carcinomas, benign serous cystoadenomas and normal ovary. Analysis of SLC34A2 gene expression according to tumor differentiation level (poor- and well-differentiated) showed that SLC34A2 is up-regulated in well differentiated tumors. CONCLUSION: Upregulation of SLC34A2 gene expression in well-differentiated tumors may reflect cell differentiation processes during ovarian cancerogenesis and could serve as potential marker for ovarian cancer diagnosis and prognosis.
Authors: Daniel J O'Shannessy; Stephen M Jackson; Natalie C Twine; Bryan E Hoffman; Zoltan Dezso; Sergei I Agoulnik; Elizabeth B Somers Journal: Int J Mol Sci Date: 2013-07-01 Impact factor: 5.923
Authors: Viktoriya B Boncheva; Michael Linnebacher; Said Kdimati; Hannah Draper; Laurence Orchard; Ken I Mills; Gerald O'Sullivan; Mark Tangney; Barbara-Ann Guinn Journal: Biomolecules Date: 2022-07-29
Authors: Mariana Lopes dos Santos; Fernanda Perez Yeda; Lilian Rumi Tsuruta; Bruno Brasil Horta; Alécio A Pimenta; Theri Leica Degaki; Ibere C Soares; Maria Carolina Tuma; Oswaldo Keith Okamoto; Venancio A F Alves; Lloyd J Old; Gerd Ritter; Ana Maria Moro Journal: PLoS One Date: 2013-07-31 Impact factor: 3.240
Authors: Thais Russo-Abrahão; Marco Antônio Lacerda-Abreu; Tainá Gomes; Daniela Cosentino-Gomes; Ayra Diandra Carvalho-de-Araújo; Mariana Figueiredo Rodrigues; Ana Carolina Leal de Oliveira; Franklin David Rumjanek; Robson de Queiroz Monteiro; José Roberto Meyer-Fernandes Journal: PLoS One Date: 2018-02-07 Impact factor: 3.240